As the downregulation of the CDX2 gene and the alteration in gut microbiota were both identified as the key determinants of GC progression and treatment failure, the link to dietary methionine metabolism could be a promising target for therapeutic exploitation in GIM. This evidence concerns the gene CDX2 and gastric cancer.